RealFeedApp Hibsago therapy approved by US regulators for hepatitis B
The FDA approved Hibsago from GSK and Ionis as a potential functional cure for adults with chronic hepatitis B without cirrhosis. The therapy is administered via six-month injections, where all but the first can be self-administered.
- Field
- drugs and trials
- What they did
- The FDA approved Hibsago, a first-of-its-kind drug from GSK and Ionis, as a potential 'functional cure' for chronic hepatitis B infections. The therapy involves six-month periodic injections for adults who have suppressed virus levels but still have active infections.
- Why it matters
- This could be useful for people already on standard antiviral therapies who wish to achieve a functional cure, as the treatment is recommended for those who have not developed cirrhosis.
#hepatitis b#fda approval#functional cure#gsk#ionis
